Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Pharmaceutical company Eli Lilly (LLY-1.04%) scored a major approval three months ago with its state-of-the-art diabetes drug, Mounjaro. It is too early to tell whether the drug will boost Lilly's ...

Pharmaceutical company Eli Lilly (NYSE: LLY) scored a major approval three months ago with its state-of-the-art diabetes drug, Mounjaro. It is too early to tell whether the drug will boost Lilly's ...

Eli Lilly and Company’s LLY stock has declined 15.7% in the past year. The first-quarter earnings miss, guidance cut and some ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Eli Lilly's strong market position is reflected in its premium valuation, trading at a P/E ratio of 86.7. ... How might increased competition impact Eli Lilly's market share in the GLP-1 space?

Eli Lilly's stock has performed well over the past year, gaining 116.84%. So far in 2024, the stock has returned 29.45% to investors.

By contrast, Eli Lilly and Novo Nordisk are already established players in the diabetes and obesity-care markets. I see both of those companies as safer and higher-conviction opportunities for ...

Eli Lilly just earned FDA approval of a treatment for ulcerative colitis. There is already plenty of competition on the market for this condition. Still, the pharmaceutical giant's product should ...

Eli Lilly & Co.'s stock was on pace for its worst day in about three years Thursday as investors fretted about intensifying competition among ... Q2 2025 in Review and Q3 2025 Market Outlook. ...

Eli Lilly continues to find ways to fend off the increasingly stiff competition in this market. Several companies are working on oral formulations of GLP-1 therapies. Others are looking into long ...

To clarify, while Eli Lilly's moat, market leadership, diversification, strong value for investment right now, and incredible pipeline trajectory make my exposure to it shrewd, it's positioning in ...